Verastem Inc (VSTM) is trading up at $10.06 (+9.23%), as of the latest quote. It is a Russell 2000 constituent in the Health Care sector.
Analyst price targets on VSTM
One firm's current price target on Verastem Inc: $18 — 79% above the current $10.1. Each is tracked to its date and scored the same way a member's call is.
- BTIG $7.97 → $18 by Oct 2027 Oct 5, 2026 via Investing.com · BTIG's track record
Targets published by research firms, extracted from the news, checked against independent reporting, and linked to their source. Where a firm did not state a horizon the target is tracked as 12 months, the industry convention; the rows where the firm set its own horizon are marked. Reported here as facts about what was published — not recommendations from Dalsna Finance, and no firm listed is affiliated with this site.
Verastem Inc revenue & net income history (FY2016–FY2025)
| FY2016Dec 2016 | FY2017Dec 2017 | FY2018Dec 2018 | FY2019Dec 2019 | FY2020Dec 2020 | FY2021Dec 2021 | FY2022Dec 2022 | FY2023Dec 2023 | FY2024Dec 2024 | FY2025Dec 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | — | — | $26.7M | $17.5M | $88.5M | $2.05M | $2.60M | — | $10.0M | $30.9M |
| Growth (year over year) | — | — | — | −34.7% | +407.1% | −97.7% | +26.4% | — | — | +209.1% |
| Gross profit | — | — | $26.6M | — | — | — | — | — | — | — |
| Gross margin | — | — | 99.4% | — | — | — | — | — | — | — |
| Operating income | −$37.0M | −$67.8M | −$94.8M | −$132.3M | −$49.4M | −$61.4M | −$72.9M | −$92.1M | −$115.0M | −$170.1M |
| Operating margin | — | — | −354.8% | −758.1% | −55.8% | −2991.2% | −2809.6% | — | −1149.6% | −550.3% |
| Net income | −$36.4M | −$67.8M | −$72.4M | −$149.2M | −$67.7M | −$71.2M | −$73.8M | −$87.4M | −$130.6M | −$209.5M |
| Net margin | — | — | −271.1% | −854.8% | −76.5% | −3468.1% | −2843.3% | — | −1306.4% | −677.6% |
| EPS (diluted) | −$11.88 | −$21.12 | −$16.44 | −$24.00 | −$5.28 | −$4.90 | −$4.57 | −$3.96 | −$3.66 | −$3.02 |
| Balance sheet | ||||||||||
| Cash and equivalents | $32.3M | $82.2M | $129.9M | $43.5M | $67.8M | $21.3M | $74.9M | $77.9M | $88.8M | $205.0M |
| Total assets | $83.6M | $89.8M | $277.2M | $145.0M | $154.3M | $108.7M | $95.0M | $149.7M | $101.5M | $246.4M |
| Total liabilities | $11.3M | $32.1M | $152.9M | $137.9M | $39.1M | $21.1M | $47.7M | $71.2M | $130.4M | $189.2M |
| Long-term debt | — | $14.8M | $25.2M | $35.1M | — | — | $24.5M | $40.1M | $40.7M | — |
| Shareholders' equity | $72.3M | $57.7M | $124.3M | $7.17M | $115.3M | $87.6M | $47.4M | $57.4M | −$28.9M | $57.2M |
| Cash flow | ||||||||||
| Operating cash flow | −$29.5M | −$57.3M | −$74.5M | −$138.5M | −$33.5M | −$53.5M | −$63.7M | −$86.5M | −$104.8M | −$137.5M |
| Capital expenditure | $39.0K | — | $1.51M | $7.00K | $33.0K | $196.0K | — | — | $28.0K | — |
| Free cash flow | −$29.5M | — | −$76.0M | −$138.5M | −$33.5M | −$53.7M | — | — | −$104.8M | — |
| Q3 FY24†Sep 2024 | Q4 FY24Dec 2024 | Q1 FY25†Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $0 | — | $0 | $2.14M | $11.2M | — | $18.7M | $40.1M |
| Growth (year over year) | — | — | — | −78.6% | — | — | — | +1775.4% |
| Operating income | −$37.0M | — | −$44.2M | −$43.8M | −$40.7M | — | −$44.9M | −$32.7M |
| Operating margin | — | — | — | −2047.9% | −362.2% | — | −240.5% | −81.6% |
| Net income | −$24.0M | — | −$52.1M | −$25.9M | −$98.5M | — | −$36.6M | −$34.7M |
| Net margin | — | — | — | −1213.6% | −876.3% | — | −196.0% | −86.5% |
| EPS (diluted) | −$0.60 | — | −$0.96 | −$0.62 | −$1.35 | — | −$0.46 | −$0.35 |
| Balance sheet | ||||||||
| Cash and equivalents | $113.2M | $88.8M | $117.6M | $164.3M | $137.7M | $205.0M | $165.6M | $136.4M |
| Total assets | $126.4M | $101.5M | $131.7M | $196.3M | $176.9M | $246.4M | $227.8M | $206.5M |
| Total liabilities | $94.2M | $130.4M | $164.1M | $160.2M | $192.4M | $189.2M | $146.0M | $156.5M |
| Long-term debt | $40.5M | $40.7M | — | — | — | — | — | — |
| Shareholders' equity | $11.1M | −$28.9M | −$32.4M | $36.1M | −$15.5M | $57.2M | $81.8M | $50.0M |
| Cash flow | ||||||||
| Operating cash flow | −$23.8M | — | −$38.7M | −$32.7M | −$36.2M | — | −$52.1M | −$43.9M |
| Capital expenditure | $0 | — | — | — | — | — | — | — |
| Free cash flow | −$23.8M | — | — | — | — | — | — | — |
From Verastem Inc's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. Net margin is our own calculation from those reported figures (net income ÷ revenue); it is left blank where revenue is zero or missing. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
About Verastem Inc
- Headquarters
- Needham, Massachusetts From SEC filings, Oct 2026
Recent News (3)
-
RBC Capital raises Verastem stock price target to $19 on G12D data RBC Capital raises Verastem stock price target to $19 on G12D data Investing.com
-
Verastem Oncology Announces Pricing of $250 Million Offering of Common Stock and Pre-Funded Warrants Verastem Oncology Announces Pricing of $250 Million Offering of Common Stock and Pre-Funded Warrants Business Wire
-
Verastem stock maintained at Buy by BTIG ahead of data readout
Verastem stock maintained at Buy by BTIG ahead of data readout
More Health Care stocks
- ILMN Illumina
- A Agilent Technologies
- ABBV AbbVie
- ABT Abbott Laboratories
- ALGN Align Technology
- ALNY Alnylam Pharmaceuticals
- AMGN Amgen
- BAX Baxter International